Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

VOR vs IMCR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

VOR Captures Overall Composite Edge (57.8 HOLD vs 46.3 HOLD), While IMCR Leads 4–2 on Growth & Valuation Pillars

VOR Overall Winner 6-Pillar Tally: VOR 2 – 4 IMCR Matrix Metrics: VOR 6 – 4 IMCR

As of Nov 16, 2026, Vor Biopharma Inc. (VOR) captures the overall head-to-head institutional edge over Immunocore Holdings plc (IMCR) on higher Unified Composite conviction (57.8/100 HOLD vs. 46.3/100 HOLD) after splitting the core matrix 6–4 (led by Profitability & Quality, Options & Positioning), while IMCR wins 4–2 across the 6-pillar growth and valuation breakdown. VOR trades at $19.26 (N/M Forward P/E, 0.0% operating margin) versus IMCR at $29.07 (23.8x Forward P/E, -2.2% operating margin).

  • Growth vs. Quality Trade-Off: VOR earns the overall head-to-head edge with a stronger Unified Composite Score (57.8/100 HOLD vs. IMCR 46.3/100 HOLD) and 1.91β · 61% Vol risk profile, whereas IMCR leads top-line expansion (-1.4% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: VOR trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 47.4); meanwhile IMCR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 42.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About VOR vs IMCR
VOR NASDAQ Head-to-Head Winner
Vor Biopharma Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$19.26
-0.82% 1D
Market Cap $1.2B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.91β · 61% Vol
Unified Composite Score
57.8 / 100 HOLD
Tech 50.0 Fund 55.0 Flow 66.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 47.4 · SMA20: $19.48 · SMA50: $19.87
IMCR NASDAQ
Immunocore Holdings plc American Depositary Shares
Biological Products, (No Disgnostic Substances)
$29.07
-2.89% 1D
Market Cap $1.6B
TTM Revenue $429M
Forward P/E 23.8x
Beta / 30D Vol 0.63β · 59% Vol
Unified Composite Score
46.3 / 100 HOLD
Tech 46.0 Fund 50.0 Flow 50.0 Mom 54.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -6.2%), weak momentum, RSI 42
RSI-14: 42.3 · SMA20: $30.96 · SMA50: $30.93

6-Pillar Scorecard Institutional Category Breakdown (VOR 2 – 4 IMCR)

Columns: Metric · VOR · IMCR
1. Valuation Multiples IMCR
Forward P/E N/M 23.8x
Trailing P/E 0.1x 23.8x
PEG Ratio N/M N/M
EV / Revenue N/M 3.7x
2. Growth & Scale IMCR
Revenue Growth (YoY) +0.0% -1.4%
Earnings Growth (YoY) +0.0% +150.0%
TTM Revenue (USD) N/A $429M
Market Cap $1.2B $1.6B
3. Profitability & Quality VOR
Gross Margin N/A 34.5%
Operating Margin 0.0% -2.2%
Net Profit Margin 0.0% -7.5%
Return on Equity (ROE) -125.4% -7.9%
4. Balance Sheet & Cash Flow IMCR
Cash Generation (TTM) -$1.63B -$5.4M EBITDA
Cash Flow Margin N/A -1.3% EBITDA Mgn
Net Cash / Leverage $1.04B Net Cash $8.13 Book/Sh · -7.9% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning VOR
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 127.0% (6th %ile) 56.7% (10th %ile)
Put/Call OI Skew 2.03x (Put-Skewed) Thin ADR Chain
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat IMCR
OpEx & R&D Intensity N/A 36.7% of Rev ($158M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: VOR (6) vs IMCR (4)
Institutional Metric VOR IMCR Criterion Row Edge
Market Capitalization
Scale
$1.2B $1.6B Larger Scale IMCR
Trailing P/E Ratio
Valuation
0.1x 23.8x Lower Multiple VOR
Forward P/E Ratio
Valuation
N/M 23.8x Lower Multiple IMCR
Revenue Growth (YoY)
Growth
+0.0% -1.4% Higher Growth VOR
Operating Margin (TTM)
Profitability
0.0% -2.2% Higher Margin VOR
Net Profit Margin
Profitability
0.0% -7.5% Higher Margin VOR
Return on Equity (ROE)
Capital Efficiency
-125.4% -7.9% Higher ROE IMCR
52-Week Range Position
Momentum
65% ($6–$26) 12% ($28–$41) Stronger Trend VOR
Beta / 30D Volatility
Risk Regime
1.91β · 61% Vol 0.63β · 59% Vol Lower Realized Risk IMCR
Unified Institutional Score
Composite Signal
57.8 / 100 (HOLD) 46.3 / 100 (HOLD) Higher Composite VOR
Trailing 12M Revenue (USD)
Operating Scale
N/A $429M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 34.5% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 3.7x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$1.63B ($1.04B Net Cash) -$5.4M EBITDA ($8.13 Book/Sh · -7.9% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon VOR +7.93 pp
VOR: +6.82% · IMCR: -1.11%
3M Horizon VOR +2.01 pp
VOR: -17.27% · IMCR: -19.28%
6M Horizon VOR +33.82 pp
VOR: +36.31% · IMCR: +2.49%
1Y Horizon VOR +115.34 pp
VOR: +97.54% · IMCR: -17.8%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on VOR vs IMCR. Trailing 12-month operating profitability (VOR 0.0% vs IMCR -2.2%) and valuation multiples (VOR N/M vs IMCR 23.8x Forward P/E) are benchmarked directly in Pillar 4 below.

VOR ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-125.4% · N/M
IMCR ADR TTM Benchmark FX-Normalized USD
TTM Revenue$429M
Gross Margin34.5%
Op. Margin-2.2%
ROE / Fwd P/E-7.9% · 23.8x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
VOR CONSOLIDATION
52d in phase · OBV NEUTRAL
Current IV 127.0%
IV Percentile 6th %ile
Put/Call OI Skew 2.03x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact VOR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
IMCR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 56.7%
IV Percentile 10th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact IMCR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
VOR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.2B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
IMCR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.6B market capitalization and -2.2% operating margin.
OpEx & R&D Reinvestment 36.7% of Rev ($158M)
90D Engineering Disclosures 0 Published

Investor FAQ VOR vs IMCR Key Questions & Quantitative Answers

As of Nov 16, 2026, Vor Biopharma Inc. (VOR) captures the overall head-to-head institutional edge over Immunocore Holdings plc (IMCR) on higher Unified Composite conviction (57.8/100 HOLD vs. 46.3/100 HOLD) after splitting the core matrix 6–4 (led by Profitability & Quality, Options & Positioning), while IMCR wins 4–2 across the 6-pillar growth and valuation breakdown. VOR trades at $19.26 (N/M Forward P/E, 0.0% operating margin) versus IMCR at $29.07 (23.8x Forward P/E, -2.2% operating margin). Growth vs. Quality Trade-Off: VOR earns the overall head-to-head edge with a stronger Unified Composite Score (57.8/100 HOLD vs. IMCR 46.3/100 HOLD) and 1.91β · 61% Vol risk profile, whereas IMCR leads top-line expansion (-1.4% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: VOR trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 47.4); meanwhile IMCR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 42.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

IMCR leads the Growth & Scale pillar: VOR posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with IMCR at -1.4% YoY revenue growth and +150.0% YoY earnings growth on $429M TTM revenue (34.5% gross margin, -2.2% operating margin). On trailing 12-month operating scale, VOR generates N/A in USD-normalized revenue versus $429M for IMCR. In operating R&D and SG&A reinvestment, VOR deploys N/A (0 90-day corporate R&D disclosures) versus 36.7% of Rev ($158M) (0 disclosures) for IMCR.

IMCR screens cheaper on headline valuation multiples. VOR trades at N/M Forward P/E, 0.1x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas IMCR trades at 23.8x Forward P/E, 23.8x Trailing P/E, N/M PEG, and 3.7x EV/Revenue (-1.3% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VOR (-125.4% ROE) versus IMCR (-7.9% ROE) capital efficiency.

In options market volatility and institutional positioning, VOR carries 127.0% implied volatility (6th %ile, Compressed (<25th %ile)), a 2.03x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.91β · 61% Vol realized risk). By comparison, IMCR carries 56.7% implied volatility (10th %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.63β · 59% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.